Our results could have translational potential: if SCRIB exon usage is confirmed to have a causative effect on survival, which can be tested in cell and animal models, molecules that can affect the exon usage of SCRIB would be good candidates for developing therapies for breast cancer and assays based on measuring SCRIB exon usage can be developed as companion diagnostics for such therapies. Here, SCRIB is linked to breast carcinoma.